BlackRock Investment Management’s Travere Therapeutics TVTX Stock Holding History

BlackRock Investment Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2.77M	Sell	146,441 -813	-0.6%	-$16.6K	﹤0.01%	1997
2016 Q3	$3.3M	Sell	147,254 -568	-0.4%	-$10.8K	﹤0.01%	1784
2016 Q2	$2.63M	Buy	147,822 +28,119	+23%	+$455K	﹤0.01%	1899
2016 Q1	$1.64M	Buy	119,703 +2,081	+2%	+$31.6K	﹤0.01%	2136
2015 Q4	$2.27M	Buy	117,622 +40	+0%	+$799	﹤0.01%	1985
2015 Q3	$2.38M	Sell	117,582 -956	-0.8%	-$28.3K	﹤0.01%	1944
2015 Q2	$3.93M	Buy	118,538 +38,713	+48%	+$1.06M	﹤0.01%	1689
2015 Q1	$1.91M	Buy	79,825 +19,083	+31%	+$291K	﹤0.01%	2059
2014 Q4	$743K	Sell	60,742 -68	-0.1%	-$704	﹤0.01%	2747
2014 Q3	$549K	Sell	60,810 -811	-1%	-$9.54K	﹤0.01%	2917
2014 Q2	$723K	Buy	61,621 +7,369	+14%	+$99.8K	﹤0.01%	2828
2014 Q1	$1.15M	Buy	+54,252	New	+$834K	﹤0.01%	2415

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Investment Management's TVTX Position: Q4 2016 in Review

BlackRock Investment Management reduced its Travere Therapeutics (TVTX) stake by 0.55% in Q4 2016, selling an estimated $16.6K and leaving 146,441 shares worth $2.77M. The position accounts for ﹤0.01% of the portfolio, ranked #1997.

BlackRock Investment Management first reported a position in TVTX in Q1 2014 and has held it in 12 quarters since. The position peaked at $3.93M in Q2 2015. 121 funds tracked by Wall St. Rank hold TVTX as of Q4 2016.

BlackRock Investment Management held 146,441 shares of Travere Therapeutics worth $2.77M as of Q4 2016.
BlackRock Investment Management sold 813 Travere Therapeutics shares in Q4 2016, an estimated $16.6K.
Travere Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #1997 holding.
BlackRock Investment Management first reported a position in Travere Therapeutics in Q1 2014 and has held it in 12 quarters since.
BlackRock Investment Management's Travere Therapeutics position peaked at $3.93M in Q2 2015.
121 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.